- AstraZeneca director buys £235,855 shares
- Computacenter director buys 8,900 shares
- Essentra non-executive director buys 70,000 shares
Michael Demare, non-executive chair of pharmaceutical giant AstraZeneca (AZN) has bought 2,000 shares at £117.93 for a total value of £235,855 on 13 September.
Demare’s move comes after the pharmaceutical giant’s shares recently fell to a one-month low after the UK’s largest quoted company released disappointing data from a late-stage clinical trial of its precision lung-cancer drug DatoDxD.
Over the past year, AstraZeneca shares have gained 8%.
COMPUTACENTER DIRECTOR BUYS 8,900 SHARES
Pauline Campbell, non-executive chair of pan-European enterprise IT infrastructure supplier Computacenter (CCC) has bought 8,900 shares at £24.70 for a total value of £219,873 on 17 September.
The company recently reported a fall in first half revenues due to a weaker than expected UK market.
Year-to-date Computacenter shares are down 9%.
ESSENTRA CO-CHAIR DESIGNATE BUYS 70,000 SHARES
Steve Good, non-executive director and co-chair designate of industrial group Essentra (ESNT) has bought 70,000 shares at 143p for a total value of £99,820 on 19 September.
Essentra shares fell by more than a quarter on 17 September after the company reported a slump in the third quarter and slashed full year guidance.
The company now expects to report a full year adjusted operating profit of £40 million to £42million, compared to market guidance of £48.4 million to £49.7million.
Good may be taking advantage of the depressed share price with his move.
Year-to-date the shares have fallen 14%.
